Pull to refresh
Logo
Daily Brief
Following Why Sign Up
FDA approves AstraZeneca's Etcamah for ESR1-mutated advanced breast cancer

FDA approves AstraZeneca's Etcamah for ESR1-mutated advanced breast cancer

New Capabilities

First cancer drug cleared based on a blood-detected resistance mutation, despite an advisory panel's 6-3 rejection

4 days ago: PFS2 and interim OS data reported from SERENA-6

Overview

Updated 3 days ago

The Food and Drug Administration approved AstraZeneca's pill Etcamah (camizestrant) on September 4, 2026, for people with metastatic breast cancer whose tumors carry an estrogen receptor-1 (ESR1) mutation. It is the first cancer therapy approved based on a resistance mutation found in blood before scans show the disease has progressed.

The approval came despite a 6-3 advisory committee vote against it on April 30. Patients switched to Etcamah in the SERENA-6 trial went a median 16 months before their disease worsened, versus 9.2 months on standard care; a follow-up put second progression at 25.7 versus 19.1 months. Whether early switching extends overall survival is still unproven, and confirmatory trials are running.

Why it matters

For women with ESR1-mutated metastatic breast cancer, a new pill delays disease progression a median of 6.8 months beyond standard care.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

51% vs 1.9%
ctDNA clearance: Etcamah vs control
Total ctDNA clearance reached 51.0% in the Etcamah arm versus 1.9% on continued aromatase inhibitor therapy in SERENA-6.
21 vs 6.4 months
Median time to health-status deterioration
Patient-reported global health status and quality of life deteriorated at a median 21 months with Etcamah versus 6.4 months on standard care.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Log in Sign Up

People Involved

Angelo de Claro, M.D.
Angelo de Claro, M.D.
Director, FDA Oncology Center of Excellence
Led the FDA review that granted accelerated approval

Organizations Involved

U.S. Food and Drug Administration
U.S. Food and Drug Administration
Federal regulatory agency
Granted accelerated approval to Etcamah on September 4, 2026

The federal agency that approves new drugs and medical devices in the United States.
AstraZeneca
AstraZeneca
Pharmaceutical company
Markets Etcamah (camizestrant) after securing FDA accelerated approval

Anglo-Swedish drugmaker that developed camizestrant, an oral estrogen receptor antagonist.
Oncologic Drugs Advisory Committee (ODAC)
Oncologic Drugs Advisory Committee (ODAC)
FDA advisory committee
Voted 6-3 against camizestrant in April 2026; FDA overruled

Independent panel of cancer experts that advises the FDA on oncology drug applications.
Guardant Health
Guardant Health
Precision oncology company
Manufacturer of the Guardant360 CDx companion diagnostic approved with Etcamah

Company whose blood test was approved to identify ESR1-mutant patients for Etcamah.

Timeline

2021 September 2026

8 events Latest: 4 days ago
Tap a bar to jump to that date

  1. PFS2 and interim OS data reported from SERENA-6

    Latest Data Release

    AstraZeneca reported time to second progression of 25.7 vs 19.1 months (HR 0.63; p=0.00373) favoring Etcamah over continued aromatase inhibitor therapy. Overall survival data remain immature (HR 0.87).

  2. News of first ctDNA-guided approval spreads

    Announcement

    Medical and mainstream outlets report Etcamah as the first blood-test-selected cancer therapy.

  3. Leerink Partners projects modest Etcamah revenues, eyes SERENA-4

    Market Analysis

    Leerink analysts estimated around $750 million in revenues for the ESR1-mutation indication, with peak revenue of roughly $2.9 billion if the first-line SERENA-4 trial succeeds. SERENA-4 data are expected in the second half of 2026.

  4. FDA grants Etcamah accelerated approval

    Regulatory Approval

    Camizestrant approved with a CDK4/6 inhibitor; Guardant360 CDx authorized as companion diagnostic.

  5. Updated survival data presented at ASCO

    Presentation

    SERENA-6 follow-up shows improved second progression-free survival at ASCO 2026.

  6. FDA delays decision to review ctDNA analyses

    Regulatory

    Agency postpones ruling to examine supplemental ctDNA clearance data.

  7. FDA panel votes 6-3 against camizestrant

    Regulatory

    ODAC says available data fail to show a clinically meaningful benefit.

  8. SERENA-6 trial launches

    Clinical Trial

    Phase 3 trial tests early switch to camizestrant when ESR1 mutations appear in blood.

Scenarios

1

Confirmatory data hold up, Etcamah wins full approval

Uncertain Resolves by End of 2028

Discussed by: ASCO Post, Pharma Now, and the FDA's Project Confirm documentation

The central question is overall survival. SERENA-6's mature survival data, likely reading out in 2027, will determine whether the accelerated approval converts into a traditional one. If the survival benefit is meaningful, Etcamah is cemented into the treatment sequence for ESR1-mutant metastatic breast cancer.

2

Overall survival disappoints, approval withdrawn

Unlikely Resolves by End of 2029

Discussed by: Pharma Now; CancerNetwork notes the conditional nature of the approval

The ctDNA-based endpoint is novel, so the confirmatory result is a genuine unknown. If mature survival data show no benefit, or the confirmatory trial fails to replicate the progression-free survival signal, the FDA can withdraw or narrow the indication under its Project Confirm framework.

3

Eetcamah moves into earlier treatment lines

Possible Resolves by Q2 2029

Discussed by: CancerNetwork; ASCO Post notes the osimertinib precedent

If confirmatory data stay positive, AstraZeneca could test camizestrant in first-line or early-stage settings, expanding the eligible population well beyond the current ESR1-mutation-defined group. The drug's benefit was consistent across common co-mutations like PIK3CA and TP53, supporting broader testing.

4

SERENA-4 readout moves Etcamah to first-line treatment

Possible Resolves by End of 2026

Discussed by: Leerink Partners analysts, via BioSpace

SERENA-4 is testing camizestrant as a first-line therapy, which would expand the eligible population well beyond the ESR1-mutation group. Leerink projects peak revenue of roughly $2.9 billion if it succeeds, versus about $750 million for the current indication. Data are expected in the second half of 2026.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

September 1998

Trastuzumab (Herceptin) with HER2 testing (1998)

The FDA approved trastuzumab for HER2-positive metastatic breast cancer, alongside a diagnostic test to identify patients whose tumors overexpressed the HER2 protein. It was one of the first targeted breast cancer therapies tied to a companion diagnostic.

Then

Herceptin became a standard of care for HER2-positive patients and transformed that subtype's outlook.

Now

Established the companion diagnostic model: a drug approved together with a test that selects the right patients.

Why this matters now

Etcamah follows the same model, pairing a targeted drug with the Guardant360 CDx blood test to find ESR1-mutant patients.

November 2015

Osimertinib (Tagrisso) for EGFR T790M (2015)

The FDA approved osimertinib for non-small cell lung cancer patients with the EGFR T790M resistance mutation, which develops during earlier EGFR inhibitor therapy. The mutation could be detected in blood or tissue before the drug was prescribed.

Then

Osimertinib became a standard second-line treatment and was later moved to first-line use.

Now

Showed how targeting an acquired resistance mutation can become a front-line therapy, expanding the eligible patient population.

Why this matters now

A recent precedent for a drug approved for a resistance mutation that later shifted to earlier lines, which Etcamah may also attempt.

2010s-2020s

FDA accelerated approvals and Project Confirm (2010s-2020s)

The FDA's accelerated approval program allows early approval based on surrogate endpoints, with confirmatory trials required afterward. Under Project Confirm, the agency tracks these trials, and drugs whose confirmatory studies fail can be withdrawn.

Then

Several drugs have been withdrawn or had their indications narrowed when confirmatory trials disappointed.

Now

Established a template where approvals are provisional: continued marketing depends on demonstrated real-world or trial benefit.

Why this matters now

Eetcamah's approval carries the same provisional condition; SERENA-6's pending overall survival data will determine whether it stays on the market.

Sources

(19)
+13
U.S. Food and Drug Administration The ASCO Post CancerNetwork Healio UPI OncoDaily Pharma Now Nova Pharma News Rojadigital Investegate (AstraZeneca announcement) Medscape Pharmaphorum MedicalDaily PharmaDossier BioSpace LSDN WebMD PharmaDeviceNews U.S. Food and Drug Administration